NBI-98854
Phase 3Small molecule
Neurocrine BiosciencesNBI-98854 is one of 91 small molecule programs targeting Schizoaffective Disorder. It is currently in Phase 3.
3
Indications
12
Total Trials
0
Active Trials
90
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
66 competitors in Schizoaffective Disorder
#DrugCompanyPhaseTrials
1Risperdal
WWim Janssens
Approved
Zyprexa
MMODAG GmbH
Approved
Depakote
TevaApproved
Nicorette
PfizerApproved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Abilify
OtsukaApproved
Diamox
TevaApproved
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Nuvigil
NNuvo Research GmbH
Approved
Haldol
DDePuy Orthopaedics
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tourette syndrome4 trials
Tardive Dyskinesia4 trials
Schizoaffective Disorder2 trials
Hepatic Insufficiency1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NBI-98854. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company